Form 8-K - Current report:
SEC Accession No. 0001193125-22-150847
Filing Date
2022-05-16
Accepted
2022-05-16 07:05:58
Documents
14
Period of Report
2022-05-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d335247d8k.htm   iXBRL 8-K 26485
2 EX-99.1 d335247dex991.htm EX-99.1 69422
6 GRAPHIC g335247g91n05.jpg GRAPHIC 14608
  Complete submission text file 0001193125-22-150847.txt   252182

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20220516.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20220516_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20220516_pre.xml EX-101.PRE 11705
8 EXTRACTED XBRL INSTANCE DOCUMENT d335247d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 22925390
SIC: 2836 Biological Products, (No Diagnostic Substances)